NCT01314937

Brief Summary

Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two. Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,760

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Sep 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 11, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 15, 2011

Completed
6 months until next milestone

Study Start

First participant enrolled

September 1, 2011

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2013

Completed
Last Updated

August 26, 2014

Status Verified

August 1, 2014

Enrollment Period

1.8 years

First QC Date

March 11, 2011

Last Update Submit

August 25, 2014

Conditions

Keywords

preschool-age childrensoil-transmitted helminthsgrowthdevelopmentdeworming

Outcome Measures

Primary Outcomes (1)

  • Mean (± standard deviation) weight gain (kg)

    Weight will be measured at baseline (12 months of age), and follow-up (18 and 24 months of age) to assess the effect of the deworming intervention on growth (in terms of weight)

    from 12 to 24 months of age

Secondary Outcomes (5)

  • Mean (± standard deviation) height gain (cm)

    from 12 to 24 months of age

  • Mean (± standard deviation) of the cognitive test score

    from 12 to 24 months of age

  • Soil-transmitted helminth infection (Ascaris, Trichuris or hookworm) - prevalence (%) and intensity (mean eggs per gram)

    from 12 to 24 months of age

  • Mean (± standard deviation) of the motor test score

    from 12 to 24 months of age

  • Mean (± standard deviation) of the language test score

    from 12 to 24 months of age

Study Arms (4)

Deworming at 12 months of age

EXPERIMENTAL
Drug: MebendazoleOther: Usual care

Deworming at 18 months of age

EXPERIMENTAL
Drug: MebendazoleOther: Usual care

Deworming at 12 and 18 months of age

EXPERIMENTAL
Drug: MebendazoleOther: Usual care

Usual care

PLACEBO COMPARATOR
Other: Usual care

Interventions

Single-dose 500 mg mebendazole tablet

Also known as: Vermox, Nemasole, Pantelmin
Deworming at 12 and 18 months of ageDeworming at 12 months of ageDeworming at 18 months of age

Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)

Also known as: Standard of care, routine health care services
Deworming at 12 and 18 months of ageDeworming at 12 months of ageDeworming at 18 months of ageUsual care

Eligibility Criteria

Age12 Months - 24 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • children attending any one of the participating study health centres for their routine 12-month growth and development visit
  • children living in or near the study area

You may not qualify if:

  • children who are attending the clinic for suspected STH infection
  • children who have received deworming treatment in the six months prior to randomization
  • parents planning to move outside of the study area within the next 12 months
  • children under 12 months of age or 14 months of age or older
  • children with serious congenital or chronic medical conditions and who would be considered by the attending staff not to benefit from deworming

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asociacion Civil Selva Amazonica

Iquitos, Loreto, Peru

Location

Related Publications (1)

  • Joseph SA, Casapia M, Montresor A, Rahme E, Ward BJ, Marquis GS, Pezo L, Blouin B, Maheu-Giroux M, Gyorkos TW. The Effect of Deworming on Growth in One-Year-Old Children Living in a Soil-Transmitted Helminth-Endemic Area of Peru: A Randomized Controlled Trial. PLoS Negl Trop Dis. 2015 Oct 1;9(10):e0004020. doi: 10.1371/journal.pntd.0004020. eCollection 2015.

MeSH Terms

Conditions

MalnutritionIntestinal Diseases, Parasitic

Interventions

MebendazoleStandard of Care

Condition Hierarchy (Ancestors)

Nutrition DisordersNutritional and Metabolic DiseasesParasitic DiseasesInfectionsIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

CarbamatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsQuality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Officials

  • Theresa W Gyorkos, PhD

    McGill University

    PRINCIPAL INVESTIGATOR
  • Martin Casapia, MD, MPH

    Asociacion Civil Selva Amazonica

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 11, 2011

First Posted

March 15, 2011

Study Start

September 1, 2011

Primary Completion

July 1, 2013

Study Completion

July 1, 2013

Last Updated

August 26, 2014

Record last verified: 2014-08

Locations